pubmed-article:8535331 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C1657587 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C0385323 | lld:lifeskim |
pubmed-article:8535331 | lifeskim:mentions | umls-concept:C0599278 | lld:lifeskim |
pubmed-article:8535331 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:8535331 | pubmed:dateCreated | 1996-2-8 | lld:pubmed |
pubmed-article:8535331 | pubmed:abstractText | The tritiated dopamine reuptake inhibitor [3H]NNC 12-0781 ([1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2,3-[3H] - propyl)-piperazine) was radiolabelled in one step starting from 1-[2-(bis(4-fluorophenyl)-methoxy)-ethyl]-4-(3-(2-furanyl)-2-propenyl)- piperazine, using tritium gas and PdO as catalyst. The radiochemical purity of [3H]NNC 12-0781 was higher than 99% after HPLC purification with a specific radioactivity of 21 Ci/mmol. [3H]NNC 12-0781 bound specifically to rat striatum in vitro at +4 degrees C with a Kd of 1.76 nM and Bmax of 587 fmol/mg tissue. The nonspecific binding was about 10% at Kd. At +37 degrees C no acceptable binding was observed. The association of [3H]NNC 12-0781 thus has the characteristics of a radioligand for the dopamine transporter in vitro at +4 degrees C. | lld:pubmed |
pubmed-article:8535331 | pubmed:language | eng | lld:pubmed |
pubmed-article:8535331 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8535331 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8535331 | pubmed:month | Aug | lld:pubmed |
pubmed-article:8535331 | pubmed:issn | 0969-8051 | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:HallHH | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:NielsenE BEB | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:MüllerLL | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:FardeLL | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:SuzdakP DPD | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:HalldinCC | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:HohlwegRR | lld:pubmed |
pubmed-article:8535331 | pubmed:author | pubmed-author:FogedCC | lld:pubmed |
pubmed-article:8535331 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8535331 | pubmed:volume | 22 | lld:pubmed |
pubmed-article:8535331 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8535331 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8535331 | pubmed:pagination | 711-7 | lld:pubmed |
pubmed-article:8535331 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:meshHeading | pubmed-meshheading:8535331-... | lld:pubmed |
pubmed-article:8535331 | pubmed:year | 1995 | lld:pubmed |
pubmed-article:8535331 | pubmed:articleTitle | Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system. | lld:pubmed |
pubmed-article:8535331 | pubmed:affiliation | Novo Nordisk A/S, Pharmaceuticals Division, Maaloev, Denmark. | lld:pubmed |
pubmed-article:8535331 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8535331 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |